Pomerantz LLP Files Class Action Lawsuit Against AeroVironment, Inc. – AVAV

AeroVironment (AVAV) faces a securities class action (26-cv-01429) alleging violations of Sections 10(b) and 20(a) / Rule 10b-5 tied to statements about the U.S. Space Force SCAR program. Since the BADGER stop-work order (Jan 20, 2026), AVAV shares fell $61.97 (-15.77%) to $330.89, then dropped another $43.93 (-17.42%) to $208.32 on March 2 after SCAR was reportedly being reassessed, and fell $13.84 (-6.24%) to $207.73 after Q3 FY2026 results including a $151.3M goodwill impairment and an operating loss of $179.0M. The lawsuit underscores investor concern over potential misstatements as the SCAR contract was terminated and the Space Force shifted toward a diversified, lower-cost approach.

Analysis

This is less a litigation story than a signal that a high-margin, single-source defense revenue stream is being normalized into a contestable procurement. That matters because niche defense names trade on the assumption that a few program wins can be valued like recurring software backlog; once the customer shifts to diversified, lower-cost sourcing, the appropriate multiple and forward margin profile both compress. The biggest hidden risk is not the legal expense itself, but the likelihood of additional non-cash write-downs if management has to re-baseline the BlueHalo acquisition thesis around a smaller SCAR contribution.

The second-order beneficiaries are broader defense primes and any contractor with scalable integration plus COTS exposure, because the customer is effectively saying it wants procurement optionality and lower vendor concentration. That favors names like LHX, NOC, RTX, and broader defense ETFs over AVAV, while also reinforcing a tougher competitive backdrop for other high-spec, single-program suppliers. Near term, the catalyst path is still messy: legal headlines can linger for weeks, but the real equity driver over 1-3 months is whether management cuts guidance again or discloses a materially lower win probability on the recompete.

The contrarian view is that a large part of the stock damage may already reflect the lost program, so additional downside depends on whether investors discover broader dependence on the same customer or another impairment. If the core drone franchise is intact and the market has already priced a permanent SCAR haircut, the short becomes a valuation call rather than a fundamental collapse call. What would falsify the bearish thesis is a credible award rebid, a settlement that preserves meaningful workshare, or a guidance reset that proves the rest of the portfolio can offset the lost contract within 2-3 quarters.

Key Decisions for Investors

• Short AVAV on any relief rally over the next 2-6 weeks; thesis is multiple compression from lost sole-source economics, not just litigation noise. Risk/reward improves if management does not quickly quantify replacement backlog.
• Pair trade: long LHX or NOC / short AVAV for 1-3 months. This expresses the view that diversified primes benefit as DoD shifts away from bespoke single-vendor awards toward broader supplier pools.
• Use AVAV weakness to buy put spreads only if implied volatility stays below the stock’s realized-event range; target a 2-3x payoff into any guidance cut or recompete update. Stop if the company regains a material share of the program.
• Avoid chasing the headline on the long side until management discloses post-SCAR backlog visibility; the key missing data is how much of 2027-2028 revenue was implicitly tied to this program.